02.01.2013 Views

Speakers - Sachs Associates

Speakers - Sachs Associates

Speakers - Sachs Associates

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Supporting Organisations<br />

Citigate Dewe Rogerson<br />

www.citigatedr.co.uk<br />

Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and<br />

corporate communications across the UK, Europe, North America and Asia.<br />

Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector<br />

and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic<br />

science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting<br />

from the company’s overall strength and from the cross-fertilisation of ideas across sectors.<br />

The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies<br />

at all stages in development. As well as core skills in financial calendar work, transactions support, financial<br />

PR and media relations, the team has extensive experience in branding, design and new media consultancy.<br />

Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging<br />

businesses in the UK, France, Germany, the Netherlands, and Scandinavia.<br />

Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public<br />

and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including;<br />

METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera<br />

Pharmaceuticals (SWX – CH88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China<br />

MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE -<br />

£35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million).<br />

Citigate Dewe Rogerson<br />

3 London Wall Buildings<br />

London Wall<br />

London EC2M 5SY<br />

Tel: +44 (0)-207-638-9571<br />

t back :: next u<br />

WELCOME PHARMA LICENSING GROUPS<br />

SPEAKERS<br />

PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />

ORGANISERS

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!